Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease

British Journal of Pharmacology

Volumn 175, Issue 3, 2018, Pages 469-484

  Wang, Weijun ^a   Zhao, Jinfang ^a   Gui, Wenfang ^a   Sun, Dan ^a   Dai, Haijiang ^b   Xiao, Li ^a   Chu, Huikuan ^a   Du, Fan ^a   Zhu, Qingjing ^c   Schnabl, Bernd ^d   Huang, Kai ^a   Yang, Ling ^a   Hou, Xiaohua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Wuhan Medical Treatment Center   (China)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TAUROURSODEOXYCHOLIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR; TAUROCHENODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE EXACERBATION; ENTERITIS; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INTESTINE FLORA; JUVENILE ANIMAL; LIPID DIET; LIPID TRANSPORT; MALE; MEMBRANE DAMAGE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA SEQUENCE; STAINING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CACO-2 CELL LINE; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SMALL INTESTINE;

ANIMALS; CACO-2 CELLS; DIET, HIGH-FAT; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOM ALLOCATION; TAUROCHENODEOXYCHOLIC ACID;

EID: 85039999057     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14095     Document Type: Article

References (69)

1. Abumrad NA, Davidson NO (2012). Role of the gut in lipid homeostasis. Physiol Rev 92: 1061–1085.
2. Abu-Shanab A, Quigley EM (2010). The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 691–701.
3. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA et al. (2017a). The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol 174: S17–S129.
4. Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017b). The Concise Guide to PHARMACOLOGY 2017/18: Catalytic receptors. Br J Pharmacol 174: S225–S271.
5. Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E et al. (2017c). The Concise Guide to PHARMACOLOGY 2017/18: Enzymes. Br J Pharmacol 174: S272–S359.
6. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M (2017). Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 65: 350–362.
7. Berger E, Haller D (2011). Structure-function analysis of the tertiary bile acid TUDCA for the resolution of endoplasmic reticulum stress in intestinal epithelial cells. Biochem Biophys Res Commun 409: 610–615.
8. Bergstrom KS, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP et al. (2010). Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog 6: e1000902.
9. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F et al. (2016). The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63: 764–775.
10. Cao SS, Zimmermann EM, Chuang BM, Song B, Nwokoye A, Wilkinson JE et al. (2013a). The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice. Gastroenterology 144: 989–1000 e1006.
11. Cao Y, Xue Y, Xue L, Jiang X, Wang X, Zhang Z et al. (2013b). Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation. J Hepatol 59: 1299–1306.
12. Carey EJ, Ali AH, Lindor KD (2015). Primary biliary cirrhosis. Lancet 386: 1565–1575.
13. Chen P, Starkel P, Turner JR, Ho SB, Schnabl B (2015). Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology (Baltimore, Md) 61: 883–894.
14. Cho EJ, Yoon JH, Kwak MS, Jang ES, Lee JH, Yu SJ et al. (2014). Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine–choline-deficient diet. Dig Dis Sci 59: 1461–1474.
15. Choi YJ, Shin HS, Choi HS, Park JW, Jo I, Oh ES et al. (2014). Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest 94: 1114–1125.
16. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I et al. (2014). Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158: 705–721.
17. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G (2011). Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology (Baltimore, Md) 54: 133–144.
18. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
19. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO et al. (2016). Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65: 426–436.
20. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L et al. (2014). Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59: 1738–1749.
21. El Aidy S, Derrien M, Aardema R, Hooiveld G, Richards SE, Dane A et al. (2014). Transient inflammatory-like state and microbial dysbiosis are pivotal in establishment of mucosal homeostasis during colonisation of germ-free mice. Benef Microbes 5: 67–77.
22. Estaki M, DeCoffe D, Gibson DL (2014). Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. World J Gastroenterol 20: 15650–15656.
23. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB et al. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110: 9066–9071.
24. Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V et al. (2017). Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology.
25. Hannah WN Jr, Harrison SA (2016). Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 64: 2234–2243.
26. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T et al. (2012). Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179–185.
27. Huse SM, Welch DM, Morrison HG, Sogin ML (2010). Ironing out the wrinkles in the rare biosphere through improved OTU clustering. Environ Microbiol 12: 1889–1898.
28. Hyysalo J, Mannisto VT, Zhou Y, Arola J, Karja V, Leivonen M et al. (2014). A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60: 839–846.
29. Itoh H, Muramatsu-Kato K, Ferdous UJ, Kohmura-Kobayashi Y, Kanayama N (2016). Undernourishment in utero and hepatic steatosis in later life: a potential issue in Japanese people. Congenit Anom (Kyoto).
30. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
31. Kim KA, Gu W, Lee IA, Joh EH, Kim DH (2012). High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One 7: e47713.
32. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 41: 1313–1321.
33. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C et al. (2013). Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62: 1787–1794.
34. Legry V, Van Rooyen DM, Lambert B, Sempoux C, Poekes L, Espanol-Suner R et al. (2014). Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. Clin Sci (Lond) 127: 507–518.
35. Leung C, Rivera L, Furness JB, Angus PW (2016). The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13: 412–425.
36. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005). Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102: 11070–11075.
37. Li K, Guo D, Zhu H, Hering-Smith KS, Hamm LL, Ouyang J et al. (2010). Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells. Am J Physiol Regul Integr Comp Physiol 299: R590–R595.
38. Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R et al. (2015). Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 1: 222–232.
39. Manco M, Putignani L, Bottazzo GF (2010). Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817–844.
40. Martinez-Moya P, Romero-Calvo I, Requena P, Hernandez-Chirlaque C, Aranda CJ, Gonzalez R et al. (2013). Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol 15: 372–380.
41. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
42. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49: 1877–1887.
43. Munukka E, Pekkala S, Wiklund P, Rasool O, Borra R, Kong L et al. (2014). Gut–adipose tissue axis in hepatic fat accumulation in humans. J Hepatol 61: 132–138.
44. Navarrete J, Vasquez B, Del Sol M (2015). Morphoquantitative analysis of the ileum of C57BL/6 mice (Mus musculus) fed with a high-fat diet. Int J Clin Exp Pathol 8: 14649–14657.
45. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO et al. (2006). Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313: 1137–1140.
46. Quevrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J et al. (2016). Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65: 415–425.
47. Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y et al. (2016). Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 151: 733–746 e712.
48. Ratziu V, Goodman Z, Sanyal A (2015). Current efforts and trends in the treatment of NASH. J Hepatol 62: S65–S75.
49. Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659–661.
50. Renga B, Mencarelli A, Cipriani S, D'Amore C, Carino A, Bruno A et al. (2013). The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS One 8: e54472.
51. Semova I, Carten JD, Stombaugh J, Mackey LC, Knight R, Farber SA et al. (2012). Microbiota regulate intestinal absorption and metabolism of fatty acids in the zebrafish. Cell Host Microbe 12: 277–288.
52. Seyhun E, Malo A, Schafer C, Moskaluk CA, Hoffmann RT, Goke B et al. (2011). Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, acinar cell damage, and systemic inflammation in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 301: G773–G782.
53. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
54. Steck N, Hoffmann M, Sava IG, Kim SC, Hahne H, Tonkonogy SL et al. (2011). Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 141: 959–971.
55. Stenman LK, Holma R, Gylling H, Korpela R. (2013). Genetically obese mice do not show increased gut permeability or faecal bile acid hydrophobicity. Br J Nutr 110: 1157–1164.
56. Takada K, Ohno N, Yadomae T (1994). Detoxification of lipopolysaccharide (LPS) by egg white lysozyme. FEMS Immunol Med Microbiol 9: 255–263.
57. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C (2016). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65: 589–600.
58. Titecat M, Wallet F, Vieillard MH, Courcol RJ, Loiez C (2014). Ruminococcus gnavus: an unusual pathogen in septic arthritis. Anaerobe 30: 159–160.
59. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027–1031.
60. Ubeda M, Lario M, Munoz L, Borrero MJ, Rodriguez-Serrano M, Sanchez-Diaz AM et al. (2016). Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 64: 1049–1057.
61. Wang Q, Garrity GM, Tiedje JM, Cole JR (2007). Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73: 5261–5267.
62. Wang W, Zhang Y, Yang L, Li H (2017). The innate immune signaling in cancer and cardiometabolic diseases: friends or foes? Cancer Lett 387: 46–60.
63. Xia L (2010). Core 3-derived O-glycans are essential for intestinal mucus barrier function. Methods Enzymol 479: 123–141.
64. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE et al. (2002). Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 36: 592–601.
65. Xin D, Zong-Shun L, Bang-Mao W, Lu Z (2014). Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease. Hepatogastroenterology 61: 136–140.
66. Yan AW, Fouts DE, Brandl J, Starkel P, Torralba M, Schott E et al. (2011). Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology (Baltimore, Md) 53: 96–105.
67. Yan L, Yang C, Tang J (2013). Disruption of the intestinal mucosal barrier in Candida albicans infections. Microbiol Res 168: 389–395.
68. Yang JS, Kim JT, Jeon J, Park HS, Kang GH, Park KS et al. (2010). Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS One 5: e13858.
69. Zarepour M, Bhullar K, Montero M, Ma C, Huang T, Velcich A et al. (2013). The mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during Salmonella enterica serovar Typhimurium colitis. Infect Immun 81: 3672–3683.